MEGAN LIEBAU: Open Payments
NPI 1306520416 · RICHMOND, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,611 in 92 payments from 18 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $1,611
Food & beverage: $1,611
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $198 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $196 |
| Vanda Pharmaceuticals Inc. | 8 | $188 |
| AstraZeneca Pharmaceuticals LP | 11 | $183 |
| Amgen Inc. | 9 | $148 |
| Teva Pharmaceuticals USA, Inc. | 9 | $144 |
| Lilly USA, LLC | 6 | $113 |
| Viatris Specialty LLC | 4 | $78 |
| Novartis Pharmaceuticals Corporation | 4 | $78 |
| Dexcom, Inc. | 2 | $49 |
Products named: CAPLYTA, AUSTEDO XR, OTEZLA, FANAPT, VRAYLAR, AIRSUPRA, QULIPTA, HETLIOZ.
Industry payments across MO — which companies pay providers there.
